Part Collection
Abstract
This year is the first year which SMMU-iGEM 2018 team becomes a family member of iGEM. We have designed 14 parts, including 6 basic parts. All of the parts are designed ourselves and most of them have been tested to insure their reliability.
As a team focusing on real-world problem, heart faliure, we found it is hard to control the process of disease through traditional drug threopy, implanted cardiac assist devices or surgical treatments. In synthetic biology, one central route is to construct a controllable biological network which could express in the environment of heart failure. We designed a targeting device, Ca2+RTIN (Cardiomyocyte RyR2 Targeting Intra-Nanobody), to implement RyR2-specific inhibition of phosphorylation.
In this year, we investigated the potential of adeno-associated virus (AAV)-9-mediated cardiac expression of AR185 which is one of the isolated nanobodies from a phage display library of variable domains of camellidae heavy chain-only antibodies (VHH) to combat post-ischemic heart failure. To achieve controlled intra-nanobody release, a BNP promoter based platform were also accessed. Our results established a role of Ca2+RTIN as a promising therapeutic approach for heart failure.
Our members are involved in the construction of the parts, and has achieved some results. The functions of all components are tested and validated under controlled laboratory conditions and normal conditions, and data and phenomena demonstrate that they are valid. At the same time, all components are standardized, which make them a convenient and powerful tool for others.
Design and Function of Ca2+RTIN
See More
To see their specific function, you can click the number link below to browse the specific page on parts.igem.org.
We listed Biobricks belong to Part Collection below.
| Favourite | Name | Type | Description | Length |
| BBa_K2865000 | Regulatory | BNP promoter, heart failure inducible | 508 | |
| BBa_K2865001 | Coding | AR185, nanobody inhibiting RyR2 phosphorylation | 1204 | |
| BBa_K2865002 | Project | [AAV9]-Left-ITR | 175 | |
| BBa_K2865003 | Project | [AAV9]-Right-ITR | 207 | |
| BBa_K2865004 | Terminator | SV40 poly(A) | 261 | |
| BBa_K2865006 | Composite | CMV promoter-eGFP-poly(A) | 1666 | |
| BBa_K2865008 | Composite | BNP promoter-eGFP-poly(A) | 1520 | |
| BBa_K2865009 | Composite | BNP-AR185-Poly(A) | 1989 | |
| BBa_K2865010 | Composite | CMV-AR185-Poly(A) | 2135 | |
| BBa_K2865012 | Composite | Left ITR-BNP-AR185-Poly(A)-Right ITR | 2387 | |
| BBa_K2865013 | Composite | Left ITR-CMV-AR185-Poly(A)-Right ITR | 2533 | |
| BBa_K2865014 | Composite | Left ITR-CMV-eGFP-Poly(A)-Right ITR | 2064 | |
| BBa_K2865015 | Composite | Left ITR-BNP-eGFP-Poly(A)-Right ITR | 1918 |
References
- Sergeeva, I.A. and V.M. Christoffels, Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta, 2013. 1832(12): p. 2403-13.
- Bingham, A.J., et al., The repressor element 1-silencing transcription factor regulates heart-specific gene expression using multiple chromatin-modifying complexes. Mol Cell Biol, 2007. 27(11): p. 4082-92.
- Kerkela, R., et al., Key roles of endothelin-1 and p38 MAPK in the regulation of atrial stretch response. Am J Physiol Regul Integr Comp Physiol, 2011. 300(1): p. R140-9.
- Lu, Y.M., et al., DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities. Cardiovasc Ther, 2009. 27(1): p. 17-27.
